While an FDA advisory panel struggled with data discrepancies this week, panel members did attempt to answer these 12 questions for the agency.
June 21, 2019
After two days of presentations regarding the death risk that may be associated with paclitaxel-coated balloons and paclitaxel-eluting stents on the market and in clinical trials, FDA learned a lot about but the agency still has a lot of work to do before any concrete decisions are made regarding the risk-benefit of the devices in question.While an FDA advisory panel struggled with data discrepancies last week, panel members did attempt to answer these 12 questions for the agency.
While an FDA advisory panel struggled with data discrepancies this week, panel members did attempt to answer these 12 questions for the agency.
About the Author(s)
You May Also Like